John Montalbano, director of Eupraxia Pharmaceuticals Inc. (TSX:EPRX), bought 22,000 Common Shares on the open market at an average of US$6.82, a US$150K purchase (about C$207K) on Aug 19, 2026.
The filing does not state its currency correctly; the price matches the stock's US-dollar trading, so it is reported in US$. The purchase increased the direct holding by about 1.4%. Montalbano now holds 1,558,139 shares directly, worth about C$15.1M at the Aug 19, 2026 close.
EPRX closed at C$9.72 on Aug 19, 2026, up 11% over the prior three months. In the 52 weeks to that date it closed between C$6.94 and C$12.50.
